Sign In
Buy ELDN
$3.81
-0.110 (-2.81%)
At Close: Jun 22, 2026
Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference
04:05pm, Wednesday, 04'th Mar 2026
IRVINE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C.
Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
04:10pm, Thursday, 05'th Feb 2026
IRVINE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steven Perrin, Ph.D.
Data from eight participants continue to support safety and tolerability profile of tegoprubart Mean eGFR increased over the measurement period, from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives $9.67 Average Price Target from Analysts
04:52am, Wednesday, 14'th Jan 2026
Shares of Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN - Get Free Report) have received an average recommendation of "Hold" from the five research firms that are covering the company, MarketBeat reports
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook
04:05pm, Thursday, 08'th Jan 2026
Phase 2 BESTOW trial data evaluating tegoprubart in kidney transplantation showed favorable efficacy, safety and tolerability, supporting advancement into Phase 3 development Reported positive prelimi
Analysts Set Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Target Price at $9.67
04:27am, Saturday, 20'th Dec 2025
Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN - Get Free Report) has received a consensus rating of "Hold" from the five research firms that are covering the stock, Marketbeat reports. One equities resea
Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference
07:00am, Monday, 01'st Dec 2025
IRVINE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C.
Eledon Reports Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation
Eledon Pharmaceuticals, Inc. (ELDN) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript
01:07pm, Monday, 17'th Nov 2025
Eledon Pharmaceuticals, Inc. ( ELDN ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 12, 2025 10:30 AM EST Company Participants Steven Perrin - President, Chief Scientific
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results
05:00pm, Friday, 14'th Nov 2025
Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrol
Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
07:56am, Wednesday, 12'th Nov 2025
IRVINE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced the pricing of its underwritten public offering of (i) 15,152,485 shares o
Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
05:26pm, Tuesday, 11'th Nov 2025
IRVINE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that it has commenced an underwritten public offering of shares of its com
Eledon Pharmaceuticals, Inc. ( ELDN ) Discusses Phase II BESTOW Trial Results and Advances in Transplantation Immunosuppression November 7, 2025 8:00 AM EST Company Participants David-Alexandre Gros -
Eledon Pharmaceuticals' Lead Asset Fails In Mid-Stage Study, But Pushes Forward With Pivotal Study
01:36pm, Friday, 07'th Nov 2025
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) stock is trading lower on Friday, with a session volume of 15.72 million, compared to its average volume of 1.24 million, according to Benzinga Pro. The comp
Data from patients who remained on tegoprubart for a year post transplant showed an overall mean 12-month estimated glomerular filtration rate (eGFR) of approximately 69 mL/min/1.73 m² Tegoprubart
